Description
Tsc-204-c0702 is an experimental therapy being studied in clinical trials for certain solid tumors, including colorectal cancer. It is a type of immunotherapy called a TCR-T cell therapy. This therapy involves collecting a patient's own immune cells (T cells), modifying them in a lab to better recognize and attack cancer cells, and then infusing these modified cells back into the patient. Specifically, Tsc-204-c0702 is designed to target the MAGE-A1 protein found on some cancer cells. Patients must have specific genetic markers (HLA type) and tumor characteristics to be eligible for this treatment. It is being tested alone (monotherapy) or in combination with other TCR-T therapies targeting different proteins.
Mechanism of Action
Tsc-204-c0702 is a T-cell receptor (TCR) T-cell therapy. It involves engineering a patient's T cells to express a specific TCR that recognizes a tumor-associated antigen (TAA), in this case, MAGE-A1. These engineered T cells are then infused back into the patient. The goal is for these modified T cells to find and destroy cancer cells that display the MAGE-A1 antigen on their surface. The therapy requires specific HLA types (HLA-C*07:02) for the TCR to effectively bind to the antigen presented by the cancer cell.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.